Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors

Clinical trial NCT05508100 · COMPLETED

Trial details

NCT number: NCT05508100
Sponsor: Immune-Onc Therapeutics
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumor

Start date: 2022-09-09
Primary completion: 2024-04-30
Enrollment: 38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.